Thomas Loughran

Publications (3)74.78 Total impact

• Article: Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report.

  Sattva S Neelapu, Barry L Gause, Daniel A Nikcevich, Stephen J Schuster, Jane Winter, Jon P Gockerman, Thomas Loughran, Ken Takeshita, Giorgio Inghirami, Dean McGaughey, [......], Miriam Ferraro, Elizabeth Jones, Elaine S Jaffe, Douglas J Schwartzentruber, David Danforth, Richard Sherry, Erik Kass, Carter Van Waes, Craig W Reynolds, Larry J Kwak
  Clinical lymphoma 07/2005; 6(1):61-4. · 3.11 Impact Factor
• Article: Phase I study of temozolomide in relapsed/refractory acute leukemia.

  Karen Seiter, Delong Liu, Thomas Loughran, Ahmad Siddiqui, Paul Baskind, Tauseef Ahmed
  [show abstract] [hide abstract]
  ABSTRACT: To determine the dose-limiting toxicity and maximum-tolerated dose of temozolomide in patients with acute leukemia. Twenty patients (16 with acute myelogenous leukemia, two with acute lymphoblastic leukemia, and two with chronic myelogenous leukemia in blastic phase) received 43 cycles of temozolomide. Patients began treatment at two different dose levels: 200 mg/m(2)/d for 7 days or 200 mg/m(2)/d for 9 days. Prolonged aplasia was the dose-limiting toxicity, and the maximum-tolerated dose was 7 days of temozolomide. Overall treatment was well tolerated: hospitalization was required in only nine of 43 courses, and there were no treatment-related deaths. Two patients obtained a complete response, and two others met criteria for complete response except for platelet recovery. Overall, nine of 20 patients had a significant decrease in bone marrow blasts after temozolomide treatment. Temozolomide was well tolerated and had significant antileukemic activity when administered as a single agent. Further studies of temozolomide in hematologic malignancies are indicated.
  Journal of Clinical Oncology 09/2002; 20(15):3249-53. · 18.37 Impact Factor
• Source

  Available from: Pascale Cony-Makhoul

  Article: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, [......], Randy Brown, Michael Schuster, Thomas Loughran, Alois Gratwohl, Franco Mandelli, Giuseppe Saglio, Mario Lazzarino, Domenico Russo, Michele Baccarani, Enrica Morra
  [show abstract] [hide abstract]
  ABSTRACT: Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.
  New England Journal of Medicine 03/2002; 346(9):645-52. · 53.30 Impact Factor